{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.2","upperLimit":"37.9","value":"15.0"},{"groupId":"OG001","lowerLimit":"15.7","upperLimit":"84.3","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"Participants with no evidence of HPV-16 and/or HPV-18 indicated the clearance of the specific HPV genotypes \\[16, 18, or both\\]. All lesions were evaluated for evidence of HPV-16/18 in vulvar tissue.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with histologically confirmed vulvar HSIL associated with HPV-16 and/or 18, received four doses of 6 mg VGX-3100 as an IM injection on Day 0, Week 4, Week 12, and Week 24 followed by EP using the CELLECTRA™ 2000 device. Participants with vulvar HSIL who had a reduction in lesion size or no increase in lesion size at Week 48, received a fifth dose of VGX-3100 at Week 52.","id":"OG000","title":"VGX-3100 + EP"},{"description":"Participants with histologically confirmed vulvar HSIL associated with HPV-16 and/or 18, received four doses of 6 mg VGX-3100 as an IM injection on Day 0, Week 4, Week 12, and Week 24 followed by EP using the CELLECTRA™ 2000 device. Participants with vulvar HSIL who had a reduction in lesion size or no increase in lesion size at Week 48, received a fifth dose of VGX-3100 at Week 52.","id":"OG001","title":"VGX-3100 + EP + Imiquimod"}],"paramType":"NUMBER","populationDescription":"mITT population included all participants who received at least 1 dose of VGX-3100 + EP (with or without imiquimod) and had an analysis endpoint of interest. 'Overall number of participants analyzed' indicates the number of participants with data available for outcome measure analysis.","reportingStatus":"POSTED","timeFrame":"Week 48","title":"Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples","type":"SECONDARY","unitOfMeasure":"percentage of participants"}